These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 15073836)

  • 21. The quinolinone derivative vesnarinone potentiates the cytotoxicity of doxorubicin in HL-60 leukemia cells.
    Yamamoto M; Maehara Y; Sakaguchi Y; Kusumoto T; Baba H; Sugimachi K
    Int J Oncol; 1997 Jan; 10(1):53-7. PubMed ID: 21533343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM; Barnett NL; Kolodny EH
    Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Not Available].
    Matsumori A
    BioDrugs; 1997 Feb; 7(2):107-18. PubMed ID: 18031085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The treatment with differentiation- and apoptosis-inducing agent, vesnarinone, of a patient with oral squamous cell carcinoma.
    Sato M; Harada K; Yura Y; Azuma M; Kawamata H; Iga H; Tsujimoto H; Yoshida H; Adachi M
    Apoptosis; 1997; 2(3):313-8. PubMed ID: 14646544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
    Bertolet BD
    Drug Saf; 2004; 27 Suppl 1():11-8. PubMed ID: 15293849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vesnarinone-induced WBC disorders in Japan.
    Matsuyama Y; Ohashi Y; Uchino H; Takaku F; Otsuka Y; Suzuki A
    Pharmacoepidemiol Drug Saf; 1996 Mar; 5(2):87-93. PubMed ID: 15073836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vesnarinone-induced granulocytopenia: incidence in Japan and recommendations for safety.
    Furusawa S; Ohashi Y; Asanoi H
    J Clin Pharmacol; 1996 May; 36(5):477-81. PubMed ID: 8739027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
    Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
    J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility of physical training after myocardial infarction and its effect on return to work, morbidity and mortality.
    Palatsi I
    Acta Med Scand Suppl; 1976; 599():7-84. PubMed ID: 16981325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preprocedural white blood cell count as a predictor of death and major adverse cardiac events in patients undergoing percutaneous coronary intervention with drug-eluting stents.
    Jurewitz DL; Pessegueiro A; Zimmer R; Bhatia R; Tobis J; Lee MS
    J Invasive Cardiol; 2009 May; 21(5):202-6. PubMed ID: 19411718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Coronary heart disease risk factors in Croatia and worldwide: results of the Interheart study].
    Carević V; Rumboldt M; Rumboldt Z;
    Acta Med Croatica; 2007 Jun; 61(3):299-306. PubMed ID: 17629106
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.